search
Back to results

The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Randomized Trial

Primary Purpose

Vitamin D Deficiency

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Vitamin D
Sponsored by
National Institute of Environmental Health Sciences (NIEHS)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Vitamin D Deficiency focused on measuring reproductive, Health, Female, Hormones, period

Eligibility Criteria

19 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers
  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Having natural, spontaneous menstrual cycles (no hormonal therapy) less than 50 days in length.
  • Aged 19-40 years
  • Ability to take a vitamin D capsule and willing to adhere to the weekly regimen
  • If sexually active, use of a non-hormonal contraceptive method.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • No menstrual period in the last 50 days, or, a typical menstrual cycle length <16 or >49 days.
  • Use of a vitamin D supplement for more than one month and on more than 15 days out of each month. Volunteers will be asked to check their supplement label for vitamin D content.
  • Unwilling to abstain from taking non-study vitamin D supplements during the study or if already taking a medically-advised vitamin D supplement.
  • Use of a calcium supplement (including certain antacids) and unwilling to abstain from taking a calcium supplement during the study.
  • Known polycystic ovarian syndrome
  • Depo-provera use in the previous 12 months
  • Current use of any hormones, including birth control
  • Current use of a hormonal intrauterine device (IUD)
  • Current pregnancy or lactation, trying to become pregnant, or planning to try in the next four menstrual cycles or 5 months.
  • History of seizure disorders
  • Celiac disease
  • Crohn s Disease
  • Body mass index >35
  • Aged <19 or > 40 years
  • Presence of known contraindications for vitamin D supplementation, history of any of the following: calcium disorder or hypercalcemia, tuberculosis or granulomatous disease, metastatic bone disease, sarcoidosis, Williams syndrome, kidney disease (kidney stones, renal failure or dialysis, lupus nephritis)
  • Known liver disease (cirrhosis)
  • History of cancer other than skin cancer.
  • History of anorexia nervosa, bulimia or an eating disorder
  • Use within the past 60 days, of exogenous hormones
  • Type 1 or Type 2 diabetes
  • Known heart disease
  • Gastric bypass surgery
  • Unwilling or unable to complete study activities, e.g. collect daily urine specimens, have blood drawn, complete daily diaries, attend in person study visits

    25. Non-English speaking

  • Due to the complexity of daily/weekly diaries, testing and procedurerequirements, all consents, instructions and questionnaires are provided in English. Therefore, all participants must be able to able to read and speak English.

Sites / Locations

  • NIEHS Clinical Research Unit (CRU)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1/High Dose Vitamin D

2/Placebo

Arm Description

Deficient women will be assigned to the Endocrine Society recommendation for deficiency, 50,000 IU/week.

Sufficient women who will receive placebo instead of Vitamin D supplementation.

Outcomes

Primary Outcome Measures

To examine the effect of vitamin D supplementation on hypothalamic-pituitary-ovarian axis hormones.
We will evaluate the extent to which vitamin D supplementation: 1) Increases urinary mid-luteal progesterone (an indicator of healthy, fertile follicle development) 2) Increases the rate of rise in urinary follicular phase estrogen (an indicator of follicular development) 3) Increases urinary pre-ovulatory LH (an indicator of healthy ovarian-hypothalamic interaction)

Secondary Outcome Measures

To quantify the increase in 25OHD and the fraction who achieve a level of 40 ng/ml after 1.5 and 3 months of supplementation, in response to 50,000 IU/week of vitamin D.
25OHD
To investigate the effect of vitamin D supplementation on the microbiome
Untargeted microbiome profiling
To investigate the effect of vitamin D supplementation on endometrial stromal cell function.
Endometrial stromal cells isolated from menstrual effluent.
To examine the change in whole blood metals levels in response to vitamin D supplementation.
Whole blood lead
Determine the impact of Vitamin D supplementation in reproductive-aged women by assaying the metabolome before and after vitamin D supplementation.
Untargeted metabolomics

Full Information

First Posted
September 18, 2021
Last Updated
October 6, 2023
Sponsor
National Institute of Environmental Health Sciences (NIEHS)
search

1. Study Identification

Unique Protocol Identification Number
NCT05050916
Brief Title
The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Randomized Trial
Official Title
The Investigation of Vitamin D and Menstrual Cycles Trial: A Phase II Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 3, 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 17, 2023 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
November 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Environmental Health Sciences (NIEHS)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Background: About 1.5 million U.S. women of reproductive age are estimated to be infertile. Many more have difficulty getting pregnant. Menstrual cycles are an indicator of a woman s general health. Menstrual cycle changes may predict difficulties in getting pregnant. Researchers want to see what role vitamin D may play in menstrual cycle health. Objective: To examine the effect of vitamin D supplementation on the hormones that come from the brain and the ovary during a menstrual cycle. Eligibility: Women aged 19-40 who have spontaneous menstrual cycles (are not taking any hormones) less than 50 days in length. Design: Participants will fill out a screening survey about their demographics and health history. It will take 5-10 minutes to complete. Participants will have 3 study visits. Participants who are deficient will be randomized to receive either a lower or higher dose of vitamin D supplements. Participants who are sufficient will receive placebo. If they are vitamin D deficient, they will not get the placebo. They will take the capsules by mouth, once per week, for 3 menstrual cycles (or about 90 days). Participants will have physical exams. Their height, weight, body fat percentage, blood pressure, and waist-hip ratio will be measured. They will give blood samples. They will have vaginal and oral swabs. Participants will keep a daily menstrual diary. They will do daily home ovulation testing. They will collect urine at home. Some women may collect menstrual blood at home. Participants will fill out an online survey. It will ask about their health, diet, and physical activity; birth control use; pregnancy history; menstrual cycle; smoking and drinking habits; education; and occupation. It will take 20-30 minutes to complete. Participation will last for four menstrual cycles (about 4 months).
Detailed Description
Study Description: This Phase II randomized, dose-ranging clinical trial translates both animal studies and human observational research into public health relevant research. We will investigate vitamin D s influence on the hypothalamic-pituitary-ovarian axis by careful evaluation of hormonal and ovulatory menstrual cycle changes that occur with vitamin D supplementation. Vitamin D supplementation may be a low-cost intervention that improves menstrual cycle function and fertility. After recruitment, there will be two phases to this study: Phase 1 will follow all women for at least one menstrual cycle prior to supplementation, the pre-supplementation cycle . During Phase 1, blood will be drawn and assayed for 25-hydroxyvitamin D (25OHD). If their level is less than 20 ng/ml (deficiency), they will be invited to participate in Phase 2. A small sample of participants with a level >= 20 ng/ml will also be invited to participate in Phase 2, to maintain participant blinding. Participation ends for the remaining women whose level is 20 ng/ml or higher. During Phase 2, deficient women receive a blinded dose of 50,000 IU of vitamin D supplementation per week. The small group of sufficient women will receive a placebo. Participants will not be told what their 25OHD level was or what group they are in. Women will be followed for three more menstrual cycles. In the presupplementation cycle and in the last of these three cycles, the supplemented cycle , women will collect daily urine specimens. Hormone levels will be compared between the pre-and postsupplementation cycles as the primary analysis. A secondary analysis will compare the supplemented cycles in the deficient women who received 50,000 IU and the deficient women who received placebo. The original design of this trial included a low-dose (4,200 IU) vitamin D supplementation arm. At entry into Phase 2, participants were randomized to receive the 4,200 IU vitamin D supplement or 50,000 IU vitamin D supplement in a 2:3 ratio. The low-dose arm of the trial has been discontinued for cost and efficiency purposes. As of 12/13/22, 16 participants were randomized to receive the low-dose vitamin D supplement. On approval of the current document, this information will be updated to reflect the final count of participants who received the low-dose vitamin D supplement and the specific date at which the low-dose arm was discontinued via a future amendment. Study data for women who received the low-dose vitamin D supplement will be retained for research and analysis. Specific analyses, biospecimen use, and statistical comparisons will not differ from those described below for the participants who receive the 50,000 IU vitamin D supplement or the placebo. All data handling and security procedures described in this document equivalently apply to data collected from participants receiving the low-dose vitamin D supplement. The primary aim of this trial will test the following hypotheses by comparing vitamin D supplemented cycles to the presupplementation cycles, within-woman: (1) Mid-luteal progesterone is higher in vitamin D supplemented cycles; (2) Rate of estrogen rise is higher in vitamin D supplemented cycles; (3) Pre-ovulatory LH is higher in vitamin D supplemented cycles. Objectives: Primary objective: -To examine the effect of vitamin D supplementation on hypothalamic-pituitary-ovarian axis hormones. We will evaluate the extent to which vitamin D supplementation: Increases urinary mid-luteal progesterone (an indicator of healthy, fertile follicle development) Increases the rate of rise in urinary follicular phase estrogen (an indicator of follicular development) Increases urinary pre-ovulatory LH (an indicator of healthy ovarian-hypothalamic interaction) Secondary objectives: Determine the impact of vitamin D supplementation in reproductive-aged women by assaying the metabolome before and after vitamin D supplementation To quantify the increase in 25OHD and the fraction who achieve a level of 40 ng/ml after 1.5 and 3 months of supplementation, in response to 50,000 IU/week of vitamin D. To examine the effects of vitamin D supplementation on endometrial stromal cell decidualization Tertiary/Exploratory objectives: To examine the change in whole blood metals levels in response to vitamin D supplementation. To examine the change in vaginal or oral microbiome in response to vitamin D supplementation. To investigate the extent to which vitamin D reduces the incidence of --delayed ovulation (follicular phase >20 days), 2) short luteal phase (<=10 days), and 3) long cycles (>34 days) To investigate the association between 25OHD levels, sleep measures, physical activity, exposure to white/red/green/blue light, and hypothalamic-pituitary-ovarian axis hormones. Endpoints: Primary Endpoint: Mid-luteal progesterone, follicular estrogen, preovulatory LH Secondary Endpoints: Untargeted metabolomics, 25OHD, endometrial stromal cell function, Tertiary Endpoints: metals, microbiome, ovulation, menstrual cycle length, sleep

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency
Keywords
reproductive, Health, Female, Hormones, period

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Non-Randomized
Enrollment
570 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1/High Dose Vitamin D
Arm Type
Experimental
Arm Description
Deficient women will be assigned to the Endocrine Society recommendation for deficiency, 50,000 IU/week.
Arm Title
2/Placebo
Arm Type
Placebo Comparator
Arm Description
Sufficient women who will receive placebo instead of Vitamin D supplementation.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D
Intervention Description
This is a Phase II randomized, dose-ranging clinical trial including 1) a within-woman comparison of hormones pre-and post-supplementation and 2) a comparison across women on a Vitamin D and a placebo. After recruitment, there will be two phases: Phase 1 will follow all women for one menstrual cycle prior to supplementation; blood will be assayed for 25OHD. Phase 2 includes only: 1) women with less than 20 ng/ml 25OHD ("deficient") OR 2) a sample of women with >20 ng/ml 25OHD ("sufficient") as the placebo group. During Phase 2, deficient women will be assigned to receive a blinded dose of 50,000 IU of vitamin D supplementation per week and followed for three more menstrual cycles. Hormone levels will be compared between the pre-and post-supplementation cycles as the primary analysis. The primary aim will test: if mid-luteal progesterone, rate of estrogen rise and pre-ovulatory LH are higher in vitamin D supplemented cycles.
Primary Outcome Measure Information:
Title
To examine the effect of vitamin D supplementation on hypothalamic-pituitary-ovarian axis hormones.
Description
We will evaluate the extent to which vitamin D supplementation: 1) Increases urinary mid-luteal progesterone (an indicator of healthy, fertile follicle development) 2) Increases the rate of rise in urinary follicular phase estrogen (an indicator of follicular development) 3) Increases urinary pre-ovulatory LH (an indicator of healthy ovarian-hypothalamic interaction)
Time Frame
60 months
Secondary Outcome Measure Information:
Title
To quantify the increase in 25OHD and the fraction who achieve a level of 40 ng/ml after 1.5 and 3 months of supplementation, in response to 50,000 IU/week of vitamin D.
Description
25OHD
Time Frame
60 months
Title
To investigate the effect of vitamin D supplementation on the microbiome
Description
Untargeted microbiome profiling
Time Frame
60 months
Title
To investigate the effect of vitamin D supplementation on endometrial stromal cell function.
Description
Endometrial stromal cells isolated from menstrual effluent.
Time Frame
60 months
Title
To examine the change in whole blood metals levels in response to vitamin D supplementation.
Description
Whole blood lead
Time Frame
60 months
Title
Determine the impact of Vitamin D supplementation in reproductive-aged women by assaying the metabolome before and after vitamin D supplementation.
Description
Untargeted metabolomics
Time Frame
60 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Having natural, spontaneous menstrual cycles (no hormonal therapy) less than 50 days in length. Aged 19-40 years Ability to take a vitamin D capsule and willing to adhere to the weekly regimen If sexually active, use of a non-hormonal contraceptive method. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: No menstrual period in the last 50 days, or, a typical menstrual cycle length <16 or >49 days. Use of a vitamin D supplement for more than one month and on more than 15 days out of each month. Volunteers will be asked to check their supplement label for vitamin D content. Unwilling to abstain from taking non-study vitamin D supplements during the study or if already taking a medically-advised vitamin D supplement. Use of a calcium supplement (including certain antacids) and unwilling to abstain from taking a calcium supplement during the study. Known polycystic ovarian syndrome Depo-provera use in the previous 12 months Current use of any hormones, including birth control Current use of a hormonal intrauterine device (IUD) Current pregnancy or lactation, trying to become pregnant, or planning to try in the next four menstrual cycles or 5 months. History of seizure disorders Celiac disease Crohn s Disease Body mass index >35 Aged <19 or > 40 years Presence of known contraindications for vitamin D supplementation, history of any of the following: calcium disorder or hypercalcemia, tuberculosis or granulomatous disease, metastatic bone disease, sarcoidosis, Williams syndrome, kidney disease (kidney stones, renal failure or dialysis, lupus nephritis) Known liver disease (cirrhosis) History of cancer other than skin cancer. History of anorexia nervosa, bulimia or an eating disorder Use within the past 60 days, of exogenous hormones Type 1 or Type 2 diabetes Known heart disease Gastric bypass surgery Unwilling or unable to complete study activities, e.g. collect daily urine specimens, have blood drawn, complete daily diaries, attend in person study visits 25. Non-English speaking Due to the complexity of daily/weekly diaries, testing and procedurerequirements, all consents, instructions and questionnaires are provided in English. Therefore, all participants must be able to able to read and speak English.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Olivia S Kohrman
Phone
(919) 287-4533
Email
olivia.kohrman@nih.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Marie Z Jukic, Ph.D.
Phone
(984) 287-3699
Email
jukica@niehs.nih.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Marie Z Jukic, Ph.D.
Organizational Affiliation
National Institute of Environmental Health Sciences (NIEHS)
Official's Role
Principal Investigator
Facility Information:
Facility Name
NIEHS Clinical Research Unit (CRU)
City
Research Triangle Park
State/Province
North Carolina
ZIP/Postal Code
27709
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NIEHS Join A Study Recruitment Group
Phone
855-696-4347
Email
myniehs@nih.gov

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Links:
URL
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_000476-E.html
Description
NIH Clinical Center Detailed Web Page

Learn more about this trial

The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Randomized Trial

We'll reach out to this number within 24 hrs